Blood tests play a vital role in the management of chronic diseases by providing critical data on disease progression and ...

Throughout September, the FDA approved drugs for the treatment of diseases including lung cancer, multiple myeloma, thyroid ...

In less than a month, from August 20 to September 19, amivantamab (Ami; Rybrevant, Johnson & Johnson) received 2 approvals ...

SCLC most commonly occurs in heavy smokers, but this type of tumor also develops in a significant number of patients with lung adenocarcinomas, particularly after treatment with therapies that target ...

FDA has approved Tagrisso for the treatment of adult patients with locally advanced, unresectable NSCLC whose disease has not progressed during or following concurrent or sequential platinum-based ...

For patients with obesity, type 2 diabetes, and estimated glomerular filtration rate (eGFR) 20 to 60 mL/min/1.73 m2, metabolic surgery is associated with a lower risk for progression of kidney ...

EGFR is a protein on the surface of cells ... Your doctor can tell you what drug is available for you. You have treatment through a thin short tube (a cannula) that goes into a vein in your arm each ...

NKT2152 makes strides in RCC, the amivantamab/chemotherapy combination receives approval for EGFR-mutant NSCLC, and experts discuss the future of AML. We also highlight the approval of the 420-mg dose ...

Lung cancer is rare in people under 45, but rates are rising in non-smokers, particularly women. Tiffany Job was shocked to ...

The US Food and Drug Administration (FDA) has approved osimertinib (Tagrisso, AstraZeneca Pharmaceuticals) for the treatment ...

The FDA has approved AstraZeneca's Tagrisso for treating unresectable, Stage III EGFR-mutated non-small cell lung cancer, ...

In June, at the American Society of Clinical Oncology (ASCO) conference in Chicago, when AstraZeneca discussed results from a ...